# Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging

> **NCT07527806** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 156 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Trastuzumab (Herceptin)
- **DRUG:** Pertuzumab
- **DRUG:** Combination product: Trastuzumab + Pertuzumab
- **DRUG:** Docetaxel or Nab-paclitaxel
- **DRUG:** carboplatin
- **DRUG:** CDK4/6 inhibitor
- **DRUG:** Aromatase Inhibitor (AI)
- **DRUG:** ADC

## Key facts

- **NCT ID:** NCT07527806
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2029-05-01
- **Final completion:** 2029-12-31
- **Target enrollment:** 156 (ESTIMATED)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07527806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07527806, "Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07527806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*